Recent Analysts’ Ratings Updates for Medpace (MEDP)

Several brokerages have updated their recommendations and price targets on shares of Medpace (NASDAQ: MEDP) in the last few weeks:

• 7/13/2026 – Medpace had its price target raised by Mizuho from $495.00 to $586.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Medpace had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $547.00 price target on the stock, up from $477.00.
• 7/7/2026 – Medpace was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $515.00 price target on the stock, up from $490.00.
• 7/2/2026 – Medpace had its “hold (c+)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is owned by corporate insiders.

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.